FY22 has proven to be a great year for Diaceutics, which comfortably beat revenue expectations and maintained its EBITDA margin in the face of a transitioning business model and a highly inflationary world. It has also announced a key strategic update as well as new enterprise level agreements with two “top 10 global pharma companies”. We detail these later in the note, but together they represent $7m of data subscription agreements over 2 years, which to us further highlights the success of the conversion of this business to a platform-based subscription model.
